Evidence map›Paper›PMID 38001614›Full record

ArticleCancers2023

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary

Sergei Boichuk, Pavel Dunaev, Vera Skripova, Aigul Galembikova, Firyuza Bikinieva, Elena Shagimardanova, Guzel Gazizova, Ruslan Deviatiiarov, Elena Valeeva, Ekaterina Mikheeva and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Clinical Use of Liquid-Based Comprehensive Genomic Profiling in Gastrointestinal Stromal Tumors.Laboratory investigation; a journal of technical methods and pathology · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Sergei BoichukDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0003-2415-1084
Pavel DunaevDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Vera SkripovaBiomarker Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0002-6342-0390
Aigul GalembikovaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-0293-2974
Firyuza BikinievaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0002-9012-6525
Elena ShagimardanovaRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0003-2339-261X
Guzel GazizovaRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Ruslan DeviatiiarovRegulatory Genomics Research Center, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.ORCID 0000-0003-0019-2076
Elena ValeevaCentral Research Laboratory, Kazan State Medical University, Kazan 420012, Russia.
Ekaterina MikheevaDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.
Maria VasilyevaCytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115478, Russia.
Pavel KopninCytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115478, Russia.ORCID 0000-0002-2078-4274
Vladimir StrelnikovEpigenetics Laboratory, Research Centre for Medical Genetics, Moscow 115522, Russia.ORCID 0000-0001-9283-902X
Ramziya KiyamovaBiomarker Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
Kazan State Medical University · RUKazan Federal University · RUResearch Centre for Medical Genetics · RU

Funding

Russian Science Foundation 20-15-00001
6 · The paper itself

Abstract

We showed previously that inhibition of KIT signaling in GISTs activates FGFR-signaling pathway rendering cancer cells resistant to receptor tyrosine kinase inhibitor (RTKi) imatinib mesylate (IM) (Gleevec) despite of absence of secondary

Indexed as

autocrine pathwayc-KIT and FGFR-signalingclonal heterogeneityFGF-2gastrointestinal stromal tumor cells (GISTs)imatinib (IM)Infigratinib (BGJ 398)receptor tyrosine kinase (RTK)resistance

Identifiers

PMID38001614
PMCPMC10670741
OpenAlexW4388571949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.